Regulations.gov document
Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT…
Notice · FDA-2016-E-2525 · posted Dec 12, 2019
Key facts
| Document ID | FDA-2016-E-2525-0006 |
|---|---|
| Title | Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT INJECTION New Drug Application 205837 |
| Document type | Notice |
| Subtype | Determinations |
| Agency | FDA |
| Docket | FDA-2016-E-2525 |
| Posted | Dec 12, 2019 |
| Federal Register citation | 84 FR 67945 |
| FR document number | 2019-26812 |
| Comment period opens | Dec 12, 2019 |
| Comments due | Feb 11, 2020 |
| Effective date | Dec 12, 2019 |
At a glance
- 1–9 Pages
- No Open for comment
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: